

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA

8800465156

SRL Ltd

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: RUPALI AJAGEKAR PATIENT ID: RUPAF200882181A

ACCESSION NO: 0181VI000861 AGE: 40 Years SEX: Female

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final** 

# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE				
COLOR	PALE YELLOW			
METHOD: VISUAL INSPECTION				
APPEARANCE	CLEAR			
METHOD: VISUAL INSPECTION				
SPECIFIC GRAVITY	1.005		1.003 - 1.035	
METHOD: IONIC CONCENTRATION METHOD				
BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN	13.2		12.0 - 15.0	g/dL
METHOD: SLS-HEMOGLOBIN DETECTION METHOD				
RED BLOOD CELL COUNT	3.94		3.8 - 4.8	mil/µL
METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION				
WHITE BLOOD CELL COUNT	5.41		4.0 - 10.0	thou/µL
METHOD: FLUORESCENCE FLOW CYTOMETRY				
PLATELET COUNT	345		150 - 410	thou/µL
METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION				
RBC AND PLATELET INDICES				
HEMATOCRIT	38.9		36.0 - 46.0	%
METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD				
MEAN CORPUSCULAR VOL	98.7		83.0 - 101.0	tL
METHOD: CALCULATED FROM RBC & HCT				
MEAN CORPUSCULAR HGB.	33.5	High	27.0 - 32.0	pg
METHOD: CALCULATED FROM THE RBC & HGB				
MEAN CORPUSCULAR HEMOGLOBIN	33.9		31.5 - 34.5	g/dL
CONCENTRATION  METHOD: CALCULATED FROM THE HGB & HCT				
MENTZER INDEX	25.1			
RED CELL DISTRIBUTION WIDTH	14.0		11.6 - 14.0	%
METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE				
MEAN PLATELET VOLUME	9.7		6.8 - 10.9	fL
METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMAT	TOCRIT			
CHEMICAL EXAMINATION, URINE				
P⊢	6.0		4.7 - 7.5	
METHOD: DOUBLE INDICATOR PRINCIPLE				
PROTEIN	NOT DETECTED		NOT DETECTED	



METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID

Page 1 Ot 13 Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID: RUPAF200882181A

Email: customercare.thane@srl.in

PATIENT NAME: RUPALI AJAGEKAR

ACCESSION NO: 0181VI000861 AGE: 40 Years SEX: Female

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units
GLUCOSE	NOT DETECTED	NOT DETECTED	
METHOD : GLUCOSE OXIDASE PEROXIDASE			
KETONES	NOT DETECTED	NOT DETECTED	
METHOD: NITROPRUSSIDE REACTION			
BLOOD	NOT DETECTED	NOT DETECTED	
METHOD: PEROXIDASE			
UROBILINOGEN	NORMAL	NORMAL	
METHOD: MODIFIED EHRLICH REACTION	NOT DETECTED	NOT DETECTED	
NITRITE	NOT DETECTED	NOT DETECTED	
METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
WBC DIFFERENTIAL COUNT - NLR			
SEGMENTED NEUTROPHILS	64	40 - 80	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE NEUTROPHIL COUNT	3.46	2.0 - 7.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	0.7	20 40	0/
LYMPHOCYTES	27	20 - 40	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	1 44	10.30	thousest
ABSOLUTE LYMPHOCYTE COUNT  METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	1.44	1.0 - 3.0	thou/µL
NEUTROPHIL LYMPHOCYTE RATIC (NLR)	2.4		
` '	5	1 - 6	%
EOSINOPHILS  METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	5	1 - 6	%0
ABSOLUTE EOSINOPHIL COUNT	0.29	0.02 - 0.50	thou/µL
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	0.29	0.02 - 0.50	ti lod/µL
MONOCYTES	4	2 - 10	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	٦	2 10	70
ABSOLUTE MONOCYTE COUNT	0.23	0.2 - 1.0	thou/µL
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING	3.23	0.2 2.0	a o a, p
DIFFERENTIAL COUNT PERFORMED ON:	EDTA SMEAR		
MICROSCOPIC EXAMINATION, URINE			
PUS CELL (WBC'S)	1-2	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION			,
EPITHELIAL CELLS	0-1	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION			•
ERYTHROCYTES (RBC'S)	NOT DETECTED	NOT DETECTED	/HPF
METHOD: MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID: RUPAF200882181A

Email: customercare.thane@srl.in

PATIENT NAME: RUPALI AJAGEKAR

ACCESSION NO: 0181VI000861 AGE: 40 Years SEX: Female

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interv	val Units
METHOD & MICROSCODIC EVAMINATION			
METHOD: MICROSCOPIC EXAMINATION  CRYSTALS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION	NOI DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION	NOT BETECTED	NOT BETECTED	
YEAST	NOT DETECTED	NOT DETECTED	
MORPHOLOGY	1101 02120120	1,61 52123123	
RBC	NORMOCYTIC NORMO	CHROMIC	
WBC	NORMAL MORPHOLOG		
METHOD: MICROSCOPIC EXAMINATION	NORMAL MORPHOLOG	I	
PLATELETS	ADEQUATE		
ERYTHRO SEDIMENTATION RATE, BLOOD	no E Quan E		
SEDIMENTATION RAIL (ESR)	20	0 - 20	mm at 1 hr
METHOD: WESTERGREN METHOD	20	0 20	IIIIII GC I III
GLUCOSE, FASTING, PLASMA			
GLUCOSE, FASTING, PLASMA	93	Normal 75 - 99	mg/dL
	55	Pre-diabetics: 100 - 125 Diabetic: > or = 126	mg, ac
METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE			
GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE B	LOOD		
GLYCOSYLATED HEMOGLOBIN (HBA1C)	4.7	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%
METHOD: HPLC			
MEAN PLASMA GLUCOSE	88.2	< 116.0	mg/dL
METHOD: CALCULATED PARAMETER			
GLUCOSE, POST-PRANDIAL, PLASMA			
GLUCOSE, POST-PRANDIAL, PLASMA	86	70 - 139	mg/dL
METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE			
CORONARY RISK PROFILE, SERUM			
CHOLESTEROL	204 F	High Desirable cholesterol level < 200 Borderline high cholesterol 200 - 239 High cholesterol > / = 240	mg/dL
METHOD : ENZYMATIC COLOPIMETRIC ASSAY		,	

METHOD: ENZYMATIC COLORIMETRIC ASSAY



Page 3 Ot 13 Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower,Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email: customercare.thane@srl.in

SRL Ltd

PATIENT ID: RUPAF200882181A

PATIENT NAME: RUPALI AJAGEKAR

ACCESSION NO: 0181VI000861 AGE: 40 Years

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

SEX: Female

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
TRIGLYCERIDES  METHOD: ENZYMATIC COLORIMETRIC ASSAY	143		Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
HDL CHOLESTEROL	37	Low	Low HDL Cholesterol <40	mg/dL
METHOD : ENZYMATIC, COLORIMETRIC	o.		High HDL Cholesterol >/= 60	-
CHOLESTEROL LDL	138	High	Adult levels: Optimal < 100 Near optimal/above optimal: 1 129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL 00-
METHOD: ENZYMATIC COLORIMETRIC ASSAY			,	
NON HDL CHOLESTEROL	167	High	Desirable: < 130 Above Desirable: 130 -159 Borderline High: 160 - 189 High: 190 - 219 Very high: > / = 220	mg/dL
CHOL/HDL RATIO	5.5	High	Low Risk: 3,3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0	
LDL/HDL RATIO	3.7	High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate >6.0 High Risk	Risk
VERY LOW DENSITY LIPOPROTEIN	28.6		< OR = 30.0	mg/dL
LIVER FUNCTION PROFILE, SERUM				
BILIRUBIN, TOTAL METHOD : COLORIMETRIC DIAZO	0.96		Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.30		< 0.30	mg/dL
BILIRUBIN, INDIRECT	0.66		0.1 - 1.0	mg/dL
TOTAL PROTEIN  METHOD: COLORIMETRIC	7.6		6.0 - 8.0	g/dL
ALBUMIN METHOD: COLORIMETRIC	4.9		3.97 - 4.94	g/dL
GLOBULIN	2.7		2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.8		1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: UV ABSORBANCE	21		< OR = 35	U/L







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower,Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email: customercare.thane@srl.in

SRL Ltd

PATIENT ID: RUPAF200882181A

PATIENT NAME: RUPALI AJAGEKAR

ACCESSION NO: 0181VI000861 AGE: 40 Years SEX: Female

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

ALANINE AMINOTRANSFERASE (ALT/SGPT) 13	Test Report Status <u>Final</u>	Results		Biological Reference	Interval Units
METHOD: WASSCRANCE  ALKALINE PHOSPHATASE  METHOD: COLORIMETRIC  GAMMA GLUTAMYL TRANSFERASE (GGT)  METHOD: ENZWATIC, COLORIMETRIC  LACTATE DEHTOROGENASE  METHOD: WASSCRANCE  SERUM BLOOD UREA NITROGEN  CREATININE, SERUM  CREATININE, SERUM  CREATININE, SERUM  CREATININE, SERUM  CREATININE, SERUM  CREATININE  BUN/CREAT RATIO  BUN/CR	ALANDAG AMINOTDANICEEDACE (ALTICODE)	10		4 OD - OF	1.121
ALKALINE PHOSPHATASE   92   35 - 104   U/L     METHOD: COLORIMETRIC   GAMMA GLUTAML TRANSFERASE (GGT)   3.40   0 - 40   U/L     METHOD: ENZIMATIC, COLORIMETRIC   U/L     METHOD: ENZIMATIC, COLORIMETRIC   U/L     METHOD: U/RASSORBANCE   152   125 - 220   U/L     METHOD: U/RASSORBANCE   U/L     METHOD: ENZIMATIC ASSAY   U/L     METHOD: ENZIMATIC ASSAY   U/L     METHOD: COLORIMETRIC BEDING   U/L     METHOD: COLORIMETRIC BEDING   U/L     METHOD: COLORIMETRIC ASSAY   U/L     METHOD: COLORIMETRIC ASSAY   U/L     METHOD: ENZIMATIC COLORIMETRIC ASSAY   U/L     METHOD: ENZIMATIC COLORIMETRIC ASSAY   U/L     METHOD: ENZIMATIC COLORIMETRIC ASSAY   U/L     METHOD: COLORIMETRIC ASSAY   U/L     METHO		13		< UK = 35	U/L
METHOD: COLORIMETRIC GAMMA GILLTAMYL TRANSFERASE (GGT) METHOD: EXPANDIT, COLORIMETRIC  LACTATE DEHYDROGENASE LACTATE DEHYDROGENASE LACTATE DEHYDROGENASE  LACTATE DEHYDROGENASE  SERUM BLOOD UREA NITROGEN BLOOD UREA NITROGEN BLOOD UREA NITROGEN METHOD: ENZWATIC ASSAY  CREATININE, SERUM CREATININE, SERUM  CREATININE METHOD: COLORIMETRIC BUN/CREAT RATIO BUN/CREAT RATIO BUN/CREAT RATIO BUN/CREAT RATIO CURIC ACID, SERUM  LRIC ACID, SERUM  TOTAL PROTEIN, SERUM  TOTAL PROTEIN, SERUM  TOTAL PROTEIN ABBUMIN, SERUM ALBUMIN, SERUM  ALBUMIN, SERUM  ALBUMIN, SERUM  ALBUMIN, SERUM  ALBUMIN, SERUM  GLOBULIN GLOCIORIMETRIC  BUN/CREAT RATIO  BUN/CREAT RATIO  BUN/CREAT RATIO BUN/C		92		35 - 104	U/I
METHOD: ENZYMATIC, COLORIMETRIC   LACT ATE DEHMOR AGENASE   152   125 - 220   1/L					<u> </u>
LACTATE DEM*DROGENASE   152   125 - 220   175	GAMMA GLUTAMYL TRANSFERASE (GGT)	3.40		0 - 40	U/L
METHOD: LOV ABSCRBANCE   SERUM BLOOD UREA NITROGEN   SERUM BLOOD UREA NITROGEN   Page	METHOD : ENZYMATIC, COLORIMETRIC				
SERUM BLOOD UREA NITROGEN	LACTATE DEHYDROGENASE	152		125 - 220	U/L
BLOOD UREA NITROGEN   99	METHOD: UV AB SORBANCE				
METHOD : ENZYMATIC ASSAY   CREATININE, SERUM   CREATININE, SERUM   0.58   0.5 - 0.9   mg/dL     METHOD : COLORIMETRIC	SERUM BLOOD UREA NITROGEN				
CREATININE, SERUM           CREATININE         0.58         0.5 - 0.9         mg/dL           METHOD: COLORIMETRIC         BUN/CREAT RATIO           BUN/CREAT RATIO         15.52         High         8.0 - 15.0         URIC ACID, SERUM           URIC ACID         3.0         2.4 - 5.7         mg/dL           METHOD: ENZYMATIC COLORIMETRIC ASSAY         TOTAL PROTEIN, SERUM           TOTAL PROTEIN, SERUM         7.6         6.0 - 8.0         9/dL           METHOD: COLORIMETRIC         METHOD: COLORIMETRIC           ALBUMIN, SERUM         4.9         3.97 - 4.94         9/dL           METHOD: COLORIMETRIC         COLORIMETRIC           GLOBULIN         2.0 - 3.5         METHOD:	BLOOD UREA NITROGEN	9		6 - 20	mg/dL
CREATININE         0.58         0.5 - 0.9         mg/dL           METHOD: COLORIMETRIC         METHOD: COLORIMETRIC         METHOD: COLORIMETRIC         METHOD: COLORIMETRIC         METHOD: ENZYMATIO         MISS         Migh         8.0 - 15.0         METHOD: COLORIMETRIC ASSAY         METHOD: ENZYMATIC COLORIMETRIC ASSAY         MISS         A.4 - 5.7         mg/dL         MISS         METHOD: ENZYMATIC COLORIMETRIC ASSAY         METHOD: ENZYMATIC COLORIMETRIC ASSAY         METHOD: ENZYMATIC COLORIMETRIC ASSAY         METHOD: COLORIMETRIC         METHOD: COLORIMETRIC         METHOD: COLORIMETRIC         METHOD: COLORIMETRIC         METHOD: MET					
METHOD: COLORIMETRIC           BUN/CREAT RATIO           15.52         High         8.0 - 15.0           URIC ACID, SERUM           URIC ACID         3.0         2.4 - 5.7         mg/dL           METHOD: ENZYMATIC COLORIMETRIC ASSAY           TOTAL PROTIEIN, SERUM           TOTAL PROTIEIN, SERUM         7.6         6.0 - 8.0         g/dL           METHOD: COLORIMETRIC           ALBUMIN, SERUM         4.9         3.97 - 4.94         g/dL           METHOD: COLORIMETRIC           GLOBULIN         2.7         2.0 - 3.5         g/dL           GLOBULIN         2.7         2.0 - 3.5         g/dL           GLOBULIN         4.75         3.5 - 5.1         mmol/L           POTASSILM         4.75         3.5 - 5.1         mmol/L           CHLORIDE         101         98 - 107         mmol/L           HYPROID PANEL, SERUM           THYROID PANEL, SERUM           METHOD: ELECTROCHEMILUMINESCENCE         9.79         5.1 - 14.1         µg/dL	•				
BUN/CREAT RATIO   15.52   High   8.0 - 15.0     URIC ACID, SERUM		0.58		0.5 - 0.9	mg/dL
NUM   NUMBER   NUMB					
URIC ACID, SERUM           URIC ACID         3.0         2.4 - 5.7         mg/dL           METHOD: ENZYMATIC COLORIMETRIC ASSAY         TOTAL PROTEIN, SERUM           TOTAL PROTEIN         7.6         6.0 - 8.0         g/dL           METHOD: COLORIMETRIC         TOTAL BROTEIN         g/dL           ALBUMIN, SERUM         TOTAL PROTEIN         TOTAL PROTEIN         TOTAL PROTEIN         g/dL           ALBUMIN, SERUM         TOTAL PROTEIN         TOTAL PROTEIN         TOTAL PROTEIN         g/dL           METHOD: SULIN         2,7         2,0 - 3.5         g/dL           ELECTROLYTES (NA/K/CL), SERUM         135         Low 136 - 145         mmol/L           POTASSIUM         4,75         3.5 - 5.1         mmol/L           THYROID PANEL, SERUM         107.0         80 - 200         ng/dL           METHOD: ELECTROCHEMILUMINESCENCE         9,79         5.1 - 14.1         µg/dL	•	45.50		0.0 45.0	
METHOD: ENZYMATIC COLORIMETRIC ASSAY		15.52	High	8.0 - 15.0	
METHOD: ENZYMATIC COLORIMETRIC ASSAY           TOTAL PROTEIN, SERUM           TOTAL PROTEIN         7.6         6.0 - 8.0         g/dL           METHOD: COLORIMETRIC         WETHOD: COLORIMETRIC           ALBUMIN, SERUM         4.9         3.97 - 4.94         g/dL           METHOD: COLORIMETRIC         URL           GLOBULIN         2.7         2.0 - 3.5         g/dL           ELECTROLYTES (NA/K/CL), SERUM         135         Low         136 - 145         mmol/L           POTASSIUM         4.75         3.5 - 5.1         mmol/L           CHLORIDE         101         98 - 107         mmol/L           THYROID PANEL, SERUM         1           T3         107.0         80 - 200         ng/dL           METHOD: ELECTROCHEMILUMINESCENCE         1					
TOTAL PROTEIN, SERUM           TOTAL PROTEIN         7.6         6.0 - 8.0         g/dL           METHOD: COLORIMETRIC         ALBUMIN, SERUM           ALBUMIN         4.9         3.97 - 4.94         g/dL           METHOD: COLORIMETRIC         GLOBULIN         EVECTROLYTES (NA/K/CL), SERUM           SODIUM         2.7         2.0 - 3.5         g/dL           SODIUM         135         Low         136 - 145         mmol/L           POTASSIUM         4.75         3.5 - 5.1         mmol/L           CHLORIDE         101         98 - 107         mmol/L           THYROID PANEL, SERUM         In 107.0         80 - 200         ng/dL           METHOD: ELECTROCHEMILUMINESCENCE         FOR THE ALL T		3.0		2.4 - 5.7	mg/dL
TOTAL PROTEIN         7.6         6.0 - 8.0         g/dL           METHOD: COLORIMETRIC         4.9         3.97 - 4.94         g/dL           ALBUMIN         4.9         3.97 - 4.94         g/dL           METHOD: COLORIMETRIC         5         COLORIMETRIC         GLOBULIN         5         CULTON         GLOBULIN         9/dL           GLOBULIN         2.7         2.0 - 3.5         g/dL         9/dL           ELECTROLYTES (NA/K/CL), SERUM         135         Low         136 - 145         mmol/L           POTASSIUM         4.75         3.5 - 5.1         mmol/L           CHLORIDE         101         98 - 107         mmol/L           THYROID PANEL, SERUM         107.0         80 - 200         ng/dL           METHOD: ELECTROCHEMILUMINESCENCE         9.79         5.1 - 14.1         µg/dL					
METHOD: COLORIMETRIC           ALBUMIN, SERUM           ALBUMIN         4.9         3.97 - 4.94         g/dL           METHOD: COLORIMETRIC           GLOBULIN           GLOBULIN         2.7         2.0 - 3.5         g/dL           ELECTROLYTES (NA/K/CL), SERUM         35         Low         136 - 145         mmol/L           POTASSIUM         4.75         3.5 - 5.1         mmol/L           CHLORIDE         101         98 - 107         mmol/L           THYROID PANEL, SERUM           T3         107.0         80 - 200         ng/dL           METHOD: ELECTROCHEMILUMINESCENCE           T4         9.79         5.1 - 14.1         µg/dL           METHOD: ELECTROCHEMILUMINESCENCE		7.6		60.00	/ -11
ALBUMIN, SERUM           ALBUMIN         4.9         3.97 - 4.94         g/dL           METHOD: COLORIMETRIC           GLOBULIN           GLOBULIN         2.7         2.0 - 3.5         g/dL           ELECTROLYTES (NA/K/CL), SERUM           SODIUM         135         Low         136 - 145         mmol/L           POTASSIUM         4.75         3.5 - 5.1         mmol/L           CHLORIDE         101         98 - 107         mmol/L           THYROID PANEL, SERUM           T3         107.0         80 - 200         ng/dL           METHOD: ELECTROCHEMILUMINESCENCE           T4         9.79         5.1 - 14.1         µg/dL           METHOD: ELECTROCHEMILUMINESCENCE		7.0		0.0 - 8.0	g/aL
ALBUMIN       4.9       3.97 - 4.94       g/dL         METHOD: COLORIMETRIC       GLOBULIN         GLOBULIN       2.7       2.0 - 3.5       g/dL         ELECTROLYTES (NA/K/CL), SERUM         SODIUM       135       Low       136 - 145       mmol/L         POTASSIUM       4.75       3.5 - 5.1       mmol/L         CHLORIDE       101       98 - 107       mmol/L         THYROID PANEL, SERUM       107.0       80 - 200       ng/dL         METHOD: ELECTROCHEMILUMINESCENCE       9.79       5.1 - 14.1       µg/dL         METHOD: ELECTROCHEMILUMINESCENCE       4.99       5.1 - 14.1       µg/dL					
METHOD: COLORIMETRIC           GLOBULIN           2.7         2.0 - 3.5         g/dL           ELECTROLYTES (NA/K/CL), SERUM           SODIUM         135         Low         136 - 145         mmol/L           POTASSIUM         4.75         3.5 - 5.1         mmol/L           CHLORIDE         101         98 - 107         mmol/L           THYROID PANEL, SERUM           T3         107.0         80 - 200         ng/dL           METHOD: ELECTROCHEMILUMINESCENCE         9.79         5.1 - 14.1         µg/dL		/ Q		3 07 - 4 04	a/dl
GLOBULIN           GLOBULIN         2.7         2.0 - 3.5         g/dL           ELECTROLYTES (NA/K/CL), SERUM           SODIUM         135         Low         136 - 145         mmol/L           POTASSIUM         4.75         3.5 - 5.1         mmol/L           CHLORIDE         101         98 - 107         mmol/L           THYROID PANEL, SERUM         51         9.79         80 - 200         ng/dL           METHOD: ELECTROCHEMILUMINESCENCE         9.79         5.1 - 14.1         µg/dL	· <del></del> -· ·- ·	4.9		3.97 4.94	g/uL
GLOBULIN       2.7       2.0 - 3.5       g/dL         ELECTROLYTES (NA/K/CL), SERUM       I35       Low       136 - 145       mmol/L         SODIUM       4.75       3.5 - 5.1       mmol/L         POTASSIUM       101       98 - 107       mmol/L         CHLORIDE       101       98 - 107       mmol/L         THYROID PANEL, SERUM       107.0       80 - 200       ng/dL         METHOD : ELECTROCHEMILUMINESCENCE       9.79       5.1 - 14.1       µg/dL         METHOD : ELECTROCHEMILUMINESCENCE       4       9.79       5.1 - 14.1       1.00					
ELECTROLYTES (NA/K/CL), SERUM           SODIUM         135         Low 136 - 145         mmol/L           POTASSIUM         4.75         3.5 - 5.1         mmol/L           CHLORIDE         101         98 - 107         mmol/L           THYROID PANEL, SERUM         T3         80 - 200         ng/dL           METHOD : ELECTROCHEMILUMINESCENCE         9.79         5.1 - 14.1         µg/dL           METHOD : ELECTROCHEMILUMINESCENCE         4.79         5.1 - 14.1         µg/dL		2.7		2.0 - 3.5	a/dL
SODIUM         135         Low         136 - 145         mmol/L           POTASSIUM         4.75         3.5 - 5.1         mmol/L           CHLORIDE         101         98 - 107         mmol/L           THYROID PANEL, SERUM           T3         107.0         80 - 200         ng/dL           METHOD : ELECTROCHEMILUMINESCENCE         9.79         5.1 - 14.1         µg/dL           METHOD : ELECTROCHEMILUMINESCENCE         Hg/dL         Hg/dL         Hg/dL				2.0 0.0	g,, -:-
POTASSIUM       4.75       3.5 - 5.1       mmol/L         CHLORIDE       101       98 - 107       mmol/L         THYROID PANEL, SERUM         T3       107.0       80 - 200       ng/dL         METHOD : ELECTROCHEMILUMINESCENCE       9.79       5.1 - 14.1       μg/dL         METHOD : ELECTROCHEMILUMINESCENCE       4.75       1.7 - 14.1       μg/dL		135	Low	136 - 145	mmol/l
CHLORIDE       101       98 - 107       mmol/L         THYROID PANEL, SERUM         T3       107.0       80 - 200       ng/dL         METHOD: ELECTROCHEMILUMINESCENCE       9.79       5.1 - 14.1       µg/dL         METHOD: ELECTROCHEMILUMINESCENCE       4					
THYROID PANEL, SERUM         T3       107.0       80 - 200       ng/dL         METHOD: ELECTROCHEMILUMINESCENCE       9.79       5.1 - 14.1       μg/dL         METHOD: ELECTROCHEMILUMINESCENCE       4					
T3       107.0       80 - 200       ng/dL         METHOD : ELECTROCHEMILUMINESCENCE       9.79       5.1 - 14.1       μg/dL         METHOD : ELECTROCHEMILUMINESCENCE       μg/dL		101		50 107	mmoye
METHOD : ELECTROCHEMILUMINESCENCE  T4 9.79 5.1 - 14.1 μg/dL  METHOD : ELECTROCHEMILUMINESCENCE	-	107.0		80 - 200	na/dl
T4 9.79 5.1 - 14.1 $\mu g/dL$ METHOD: ELECTROCHEMILUMINESCENCE		107.0		00 200	rig/ aL
METHOD: ELECTROCHEMILUMINESCENCE		9.79		5.1 - 14.1	µg/dL
TSH 3RD GENERATION 1.630 0.27 - 4.2 μΙU/mL					1 5
	TSH 3RD GENERATION	1.630		0.27 - 4.2	μΙU/mL







ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA

8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: RUPALI AJAGEKAR PATIENT ID: RUPAF200882181A

ACCESSION NO: 0181VI000861 AGE: 40 Years SEX: Female

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval Test Report Status Units <u>Final</u>

METHOD: ELECTROCHEMILUMINESCENCE

PAPANICOLAOU SMEAR

TEST METHOD CONVENTIONAL GYNEC CYTOLOGY

METHOD: MICROSCOPIC EXAMINATION

SPECIMEN TYPE P-1102/22

TWO UNSTAINED CERVICAL SMEARS RECEIVED

METHOD: MICROSCOPIC EXAMINATION

2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY REPORTING SYSTEM

SPECIMEN ADEQUACY SATISFACTORY

METHOD: PAP STAIN & MICROSCOPIC EXAMINATION

THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS , FEW MICROSCOPY

INTERMEDIATE SQUAMOUS CELLS ANDFEW CLUSTERS OF ENDOCERVICAL CELLS IN THE BACKGROUND OF MODERATE

POLYMORPHS & RBC"S.

METHOD: PAP STAIN

NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY INTERPRETATION / RESULT

METHOD: PAP STAIN & MICROSCOPIC EXAMINATION

## Comments

PLEASE NOTE PAPANICOLAU SMEAR STUDY IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE SHOULD BE INTERPRETED WITH CAUTION. NO CYTOLOGICAL EVIDENCE OF HPV INFECTION IN THE SMEARS STUDIED. SMEARS WILL BE PRESERVE FOR 5 YEARS ONLY.

STOOL: OVA & PARASITE

SAMPLE NOT RECEIVED

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE AB

METHOD: GEL COLUMN AGGLUTINATION METHOD.

RH TYPE POSITIVE

METHOD: GEL COLUMN AGGLUTINATION METHOD.

XRAY-CHEST

**IMPRESSION** NO ABNORMALITY DETECTED

TMT OR ECHO

IM LOR ECHO NEGATIVE

ECG

ECG WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY NOT SIGNIFICANT



Page 6 Ot 13 Scan to View Report



ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI 8800465156

NEW DELHI 110030 DELHI INDIA

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: RUPALI AJAGEKAR PATIENT ID: RUPAF200882181A

ACCESSION NO: 0181VI000861 AGE: 40 Years SEX: Female

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units <u>Final</u>

RELEVANT PAST HISTORY MALARIA IN 2012.

COVID IN 2022. HOSPITALIZED FOR ISOLATION.

RELEVANT PERSONAL HISTORY MARRIED / 2 CHILD / VEG DIET / NO ALLERGIES / NO SMOKING / NC

ALCOHOL.

MENSTRUAL HISTORY (FOR FEMALES) IRREGULAR 15-45 DAYS/3

LMP (FOR FEMALES) 31/8/2022 OBSTETRIC HISTORY (FOR FEMALES) 1FTNDA0L1

1 PRETERM DELIVERY. LCB (FOR FEMALES) 15 YEARS BACK.

RELEVANT FAMILY HISTORY HIGH BLOOD PRESSURE & HEART DIASEASE: FATHER.

HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.54 mts WEIGHT IN KGS. 56 Kgs BMI 24 BMI & Weight Status as follows: kg/sqmts

> Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL PHYSICAL ATTITUDE NORMAL GENERAL APPEARANCE / NUTRITIONAL STATUS **HEALTHY** BUILT / SKELETAL FRAMEWORK **AVERAGE** FACIAL APPEARANCE NORMAL SKIN NORMAL UPPER LIMB NORMAL LOWER LIMB NORMAL NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED CAROTID PULSATION NORMAL **TEMPERATURE** NORMAL

80/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID PULSE

BRUIT

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM



Page 7 Ot 13 Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA

8800465156

SRL Ltd

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: RUPALI AJAGEKAR PATIENT ID: RUPAF200882181A

ACCESSION NO: 0181VI000861 AGE: 40 Years SEX: Female

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

REFERRING DOCTOR: SELF	OCTOR: SELF CLIENT PATIENT ID:	
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
BP	130/80 MM HG (SUPINE)	mm/Hg
PERICARDIUM	NORMAL	
APEX BEAT	NORMAL	
HEART SOUNDS	NORMAL	
MURMURS	ABSENT	
RESPIRATORY SYSTEM		
SIZE AND SHAPE OF CHEST	NORMAL	
MOVEMENTS OF CHEST	SYMMETRICAL	
BREATH SOUNDS INTENSITY	NORMAL	
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)	
ADDED SOUNDS	ABSENT	
PER ABDOMEN		
APPEARANCE	NORMAL	
VENOUS PROMINENCE	ABSENT	
LIVER	NOT PALPABLE	
SPLEEN	NOT PALPABLE	
HERNIA	ABSENT	
CENTRAL NERVOUS SYSTEM		
HIGHER FUNCTIONS	NORMAL	
CRANIAL NERVES	NORMAL	
CEREBELLAR FUNCTIONS	NORMAL	
SENSORY SYSTEM	NORMAL	
MOTOR SYSTEM	NORMAL	
REFLEXES	NORMAL	
MUSCULOSKELETAL SYSTEM		
SPINE	NORMAL	
JOINTS	NORMAL	
BASIC EYE EXAMINATION		
CONJUNCTIVA	NORMAL	
EYELIDS	NORMAL	
EYE MOVEMENTS	NORMAL	
CORNEA	NORMAL	
DISTANT VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT	

REDUCED VISUAL ACUITY 6/9



DISTANT VISION LEFT EYE WITHOUT GLASSES





CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA

8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: RUPALI AJAGEKAR

PATIENT ID: RUPAF200882181A

ACCESSION NO: 0181VI000861 AGE: 40 Years SEX: Female

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Biological Reference Interval **Test Report Status** Results Units <u>Final</u>

NEAR VISION RIGHT EYE WITHOUT GLASSES REDUCED VISUAL ACUITY N/18 NEAR VISION LEFT EYE WITHOUT GLASSES REDUCED VISUAL ACUITY N/18 NEAR VISION RIGHT EYE WITH GLASSES GLASSES NOT BROUGHT NEAR VISION LEFT EYE WITH GLASSES GLASSES NOT BROUGHT NORMAL

COLOUR VISION

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT

RELEVANT GP EXAMINATION FINDINGS REDUCED ACUITY FOR NEAR VISION.

REMARKS / RECOMMENDATIONS 1) FOLLOW UP WITH GYNAECOLOGIST FOR IRREGULAR MENSES.

2) LOW FAT, LOW CARBOHYDRATE, HIGH FIBRE DIET.

3) REGULAR EXERCISE.REGULAR WALK FOR 30-40 MIN DAILY.

4) REPEAT LIPID PROFILE AFTER 3 MONTHS OF DIET AND EXERCISE.

## Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-

The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. WBC DIFFERENTIAL COUNT - NLR-

The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504. This ratio element is a calculated parameter and out of NABL scope.

MICROSCOPIC EXAMINATION, UNINE-

Routing uring analysis assists in screening and diagnosis of various metabolic, urological, kidney and liver, disorders

Protein: Elevated proteins car be an early sign of kidney disease. Urinary protein excretion can also be temporarily elevated by strenuous exercise, orthostatic proteinuria, dehydration, urinary tract infections and acute illness with fever
Glucose: Uncontrolled diabetes mellitus can lead to presence of glucose in urine. Other causes include pregnancy, hormonal disturbances, liver disease and certain

medications.

Ketones: Uncontrolled diabetes mellitus car lead to presence of ketones in urine. Ketones can also be seen in starvation, frequent vomiting, pregnancy and strenuous

Blood: Occult blood can occur in urine as intact erythrocytes or haemoglobin, which can occur in various urological, nephrological and bleeding disorders. Leukocytes: An increase in leukocytes is an indication of inflammation in urinary tract or kidneys. Most common cause is bacterial urinary tract infection.

Nitrite: Many bacteria give positive results when their number is high. Nitrite concentration during infection increases with length of time the urine specimen is retained in bladder prior to collection.

pH: The kidneys play an important role in maintaining acid base balance of the body. Conditions of the body producing acidosis/ alkalosis or ingestion of certain type of food can affect the pH of urine.

Specific gravity: Specific gravity gives an indication of how concentratec the urine is. Increasec specific gravity is seen in conditions like dehydration, glycosuria and proteinuria while decreased specific gravity is seen in excessive fluid intake, renal failure and diabetes insipidus Bilirubin: In certain liver diseases such as biliary obstruction or hepatitis, bilirubin gets excreted in urine.

Urobilinogen: Positive results are seen in liver diseases like hepatitis and cirrhosis and in cases of hemolytic anemia ERYTHRO SEDIMENTATION RATE, BLOOD-

Erythrocyte sedimentation rate (ESR) is a non - specific phenomena and is clinically useful in the diagnosis and monitoring of disorders associated with an increased production of acute phase reactants. The ESR is increased in pregnancy from about the 3rd month and returns to normal by the 4th week post partium. ESR is influenced by age, sex, menstrual cycle and drugs (eg. corticosteroids, contraceptives). It is especially low (0-1mm) in polycythaemia, hypofibrinogenemia or congestive cardiac failure and when there are abnormalities of the red cells such as polkilocytosis, spherocytosis or sickle cells.

- Nathan and Oski's Haematology of Infancy and Childhood, 5th edition
   Paediatric reference intervals, AACC Press, 7th edition, Edited by S. Soldin
- The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th Edition" GLUCOSE, FASTING, PLASMA-



Page 9 Ot 13 回海海通路 Scan to View Report



ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: RUPALI AJAGEKAR

PATIENT ID: RUPAF200882181A

ACCESSION NO: 0181VI000861 AGE: 40 Years SEX: Female

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval Test Report Status Units <u>Final</u>

ADA 2021 guidelines for adults, after 8 hrs fasting is as follows:

Pre-diabetics: 100 - 125 mg/dL
Diabetic: > or = 126 mg/dL
Diabetic: > or = 126 mg/dL
GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE BLOODGlycosylatec hemoglobin (GHb) has been firmly established as an index of long-term blood glucose concentrations and as a measure of the risk for the development of complications in patients with diabetes mellitus. Formation of GHb is essentially irreversible, and the concentration in the blood depends on both the life span of the reciblood cell (average 120 days) and the blood glucose concentration. Because the rate of formation of GHb is directly proportional to the concentration of glucose in the blood, the GHb concentration represents the integrated values for glucose over the preceding 6-8 weeks.

Any condition that alters the life span of the red blood cells has the potential to alter the GHb level. Samples from patients with hemolytic anemias will exhibit decreased glycated hemoglobin values due to the shortened life span of the red cells. This effect will depend upon the severity of the anemia. Samples from patients with polycythemia

or post-spienectomy may exhibit increased glycated hemoglobin values due to a somewhat longer life span of the red cells.

Glycosylated hemoglobins results from patients with HbSS, HbCC, and HbSC and HbD must be interpreted with caution, given the pathological processes, including anemia, increased red cell turnover, transfusion requirements, that adversely impact HbA1c as a marker of long-term glycemic control. In these conditions, alternative forms of testing such as glycated serum protein (tructosamine) should be considered.
"Targets should be individualized; More or less stringent glycemic goals may be appropriate for individual patients. Goals should be individualized based on duration of

diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.

- References
  1. Tretz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burbs, Edward R.Ashwood, David E Bruns, 4th Edition, Elsevier publication, 2006,
- Forsham PH. Diabetes Mellitus: A rational plan for management. Postgrad Med 1982, 71,139-154.
- 3. Mayer TK, Freedman ZR: Protein glycosylation in Diabetes Mellitus: A review of laboratory measurements and their clinical utility. Clin Chim Acta 1983, 127, 147-184. GLUCOSE, POST-PRANDIAL, PLASMA-ADA Guidelines for 2hr post prandial glucose levels is only after ingestion of 75grams of glucose in 300 ml water, over a period of 5

LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment founc in bile and is a breakdowr product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevatec levels results from increased bilirubir production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin salso elevated more than unconjugated (indirect) bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin excretion (eg, obstruction and ineffective erythropolesis), decreased bilirubin excretion (eg, obstruction ineffective erythropolesis), decreased b may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termec Gilbert syndrome, due to low levels of the enzyme that

attaches sugar molecules to bilirubin.
AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemotytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is bound mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dystunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumptor and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumir and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or c, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, mainutrition and wasting etc

SERUM BLOOD UREA NITROGEN-

Causes of Increased levels

Pre renal

- High protein diet, Increasec protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal
- Renal Failure
- Malignancy, Nephrolithiasis, Prostatism

Causes of decreased levels

- Liver disease
- SIADH.

CREATININE, SERUM-

Higher than normal level may be due to:

- Blockage in the urinary tract
- · Kidney problems, such as kidney damage or failure, infection, or reduced blood flow



Page 10 Ot 13 Scan to View Report



ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

ACCESSION NO: 0181VI000861

SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

RUPAF200882181A

Email: customercare.thane@srl.in

SRL Ltd

PATIENT NAME: RUPALI AJAGEKAR

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval Test Report Status Units <u>Final</u>

SEX: Female

• Loss of body fluid (dehydration)

· Muscle problems, such as breakdown of muscle fibers

· Problem's during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

AGE: 40 Years

Lower than normal level may be due to:

• Myasthenia Gravis

 Muscular dystrophy URIC ACID, SERUM-Causes of Increased levels Dietary

High Protein Intake.

Prolonged Fasting,Rapid weight loss.

Gout

Lesch nyhan syndrome.

Type 2 DM. Metabolic syndrome.

Causes of decreased levels

• Low Zinc Intake

Multiple Scierosis

Nutritional tips to manage increased Uric acic levels
• Drink plenty of fluids

· Limit animal proteins

High Fibre foods

Vit C Intake

Antioxidant rich foods TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc. ALBUMIN, SERUM-

Human serum albumir is the most abundant protein in human blooc plasma. It is produced in the liver. Albumin constitutes about half of the blooc serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ELECTROLYTES (NA/K/CL), SERUMSodium levels are Increased in dehydration, cushing's syndrome, aldosteronism & decreased in Addison's disease, hypopituitarism, liver disease. Hypokalemia (low K) is common in vomiting, diarrhea, alcoholism, folic acid deficiency and primary aldosteronism. Hyperkalemia may be seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid K infusion. Chloride is increased in dehydration, renal tubular acidosis (hyperchloremia metabolic acidosis), acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Chloride is decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisoniar crisis, certain types of metabolic acidosis, persistent gastric secretion and

respiratory actions, sat-losing reprints, metabolic arkaiosis, congestive heartrailure, Addisoniar crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting,
THYROID PANEL, SERUMTriiodothyronine T3 , is a thyroid hormone. It affects almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.
Thyroxine T4, Thyroxine's principal function is to stimulate the metabolism of all cells and tissues in the body. Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion; soller hyperthyroidism.

hyperthyroidism, and deficient secretion is called hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3

TOTAL TÃ TOTAL T4 Levels in (µg/dL) 6.6 **-** 12.4 (ng/dL) 81 - 190 Pregnancy (µIU/mL) 0.1 - 2.5 First Trimester

2nd Trimester 6.6 - 15.5 6.6 - 15.5 0.2 - 3.0 0.3 - 3.0 100 - 260 100 - 260 3rc Trimester Below mentioned are the guidelines for age related reference ranges for T3 and T4.

T3 (ng/dL) New Born: 75 - 260 (µg/dL) 1-3 day: 8.2 - 19.9 1 Week: 6.0 - 15.9







ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower, Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: RUPALI AJAGEKAR

PATIENT ID: RUPAF200882181A

ACCESSION NO: 0181VI000861 AGE: 40 Years SEX: Female

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval Test Report Status Units <u>Final</u>

NOTE: TSH concentrations in apparently normal euthyroid subjects are known to be highly skewed, with a strong tailed distribution towards higher TSH values. This is well documented in the pediatric population including the infant age group.

Kindly note: Method specific reference ranges are appearing or the report under biological reference range.

### Reference:

1. Burtis C.A., Ashwood E. R. Bruns D.E. Teitz textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition.

2. Gowenlock A.H. Varley's Practical Clinical Biochemistry, 6th Edition.

3. Behrman R.E. Kilegman R.M., Jenson H. B. Nelsor Text Book of Pediatrics, 17th Edition STOOL: OVA & PARASITE-

Acute infective diarrhoea and gastroenteritis (diarrhoea with vomiting) are major causes of ill health and premature death in developing countries. Loss of water and electrolytes from the body can lead to severe dehydration which if untreated, can be rapidly fatal in young children, especially that are malnourished, hypoglycaemic, and

Laboratory diagnosis of parasitic infection is mainly based on microscopic examination and the gross examination of the stool specimen. Depending on the nature of the parasite, the microscopic observations include the identification of cysts, ova, trophozoites, larvae or portions of adult structure. The two classes of parasites that cause human infection are the Protozoa and Helminths. The protozoan infections include amoebiasis mainly caused by Entamoeba histolytica and giardiasis caused by Giardia lamblia. The common helminthic parasites are Trichuris trichiura, Ascaris lumbricoides, Strongyloides stercoralis, Taenia sp. etc

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blook group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Flease note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )
F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: RUPALI AJAGEKAR

PATIENT ID: RUPAF200882181A

ACCESSION NO: 0181VI000861 AGE: 40 Years SEX: Female

DRAWN: RECEIVED: 24/09/2022 08:16 REPORTED: 27/09/2022 16:41

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final** 

# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN NO ABNORMALITIES DETECTED

> \*\*End Of Report\*\* Please visit www.srlworld.com for related Test Information for this accession

Dr. Sheetal Sawant Consultant Microbiologist

Dr. Ushma Wartikar Consultant Pathologist Dr.(Mrs)Neelu K Bhojani Lab Head



